Protecting the brain and the heart: antithrombotic treatment in nonvalvular atrial fibrillation.
Novel anticoagulants (NOACs) are the recent therapeutic breakthrough in the prophylaxis of stroke in patients with nonvalvular atrial fibrillation (NVAF). Patients with NVAF seem to have a high atherosclerotic burden, but it has not yet been established whether these agents also protect against cardiovascular disease (CVD). Different NOACs could have cardioprotective properties of different importance, but data come only from indirect comparisons. Patients with NVAF are at risk of stroke when there is concomitant atherosclerosis that also necessitates optimal treatment to reduce CVD risk. Combining antiplatelets with anticoagulants is a common clinical scenario and not always justified by current data and guidelines, putting patients at unnecessary bleeding risk. This review provides current knowledge about the cardioprotective properties of NOACs, the clinical importance of the link between CVD and NVAF, and the pitfalls of combining antiplatelet therapy with warfarin or NOACs.